Colorectal Cancer
📧 Sign up to get email alerts when something new happens for Colorectal Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-19EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
European Medicines Agency authorises Opdivo (nivolumab) for multiple cancer indications, including melanoma, non-small cell lung cancer, ren…
-
EMA approval · 2026-03-25EMA Authorised: Zirabev (bevacizumab) — Pfizer Europe MA EEIG
Zirabev (bevacizumab) has been authorised by EMA for multiple cancer indications, including colorectal, breast, non-small cell lung, renal c…
-
EMA approval · 2026-03-24EMA Authorised: Stivarga (regorafenib) — Bayer Pharma AG
The EMA authorised Stivarga (regorafenib) for colorectal cancer (colorectal neoplasms). The decision was issued on 26 February 2026.
-
EMA approval · 2026-03-18EMA Authorised: Opdivo (nivolumab) — Bristol-Myers Squibb Pharma EEIG
EMA authorised Opdivo (nivolumab) for multiple cancer indications, including melanoma, Hodgkin lymphoma, renal cell carcinoma, non-small cel…
-
FDA approval · 2026-03-17FDA Approved: OXALIPLATIN — Supplemental Application (Accord Healthcare Inc.)
FDA approves Accord Healthcare Inc.'s supplemental application for Oxaliplatin.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
FDA approval · 2026-02-03FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for STIVARGA (regorafenib) to expand its indications.
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
EMA approval · 2026-01-28EMA Authorised: Erbitux (cetuximab) — Merck Europe B.V.
EMA authorised Erbitux (cetuximab) for head and neck cancer and colorectal cancer under Merck Europe B.V.
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
FDA approval · 2026-01-15FDA Approved: OXALIPLATIN — Original Application (Shandong New Time Pharmaceutical Co., Ltd.)
The FDA approved Shandong New Time Pharmaceutical Co., Ltd.'s original application for a generic oxaliplatin injection, enabling its manufac…
-
EMA approval · 2025-11-21EMA Authorised: Yervoy (Ipilimumab) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Yervoy (ipilimumab) for multiple cancer indications. It lists melanoma, renal cell carcinoma, non-s…
-
FDA approval · 2025-11-12FDA Tentative Approval: FLUOROURACIL — Supplemental Application (Gland Pharma Limited)
FDA Tentative Approval for Fluorouracil from Gland Pharma Limited under an ANDA, indicating a pathway to U.S. market subject to regulatory t…
-
EMA approval · 2025-11-05EMA Authorised: Braftovi (Encorafenib) — Pierre Fabre Medicament
The EMA authorised Braftovi (encorafenib) for melanoma and colorectal cancer. Pierre Fabre Medicament is the marketing authorization holder.
-
FDA approval · 2025-06-17FDA Approved: CAPECITABINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Capecitabine filed by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2025-05-23FDA Approved: IRINOTECAN HYDROCHLORIDE — Supplemental Application (Sagent Pharmaceuticals)
The FDA approved a supplemental application for irinotecan hydrochloride submitted by Sagent Pharmaceuticals, indicating an approval of chan…
-
EMA approval · 2025-05-05EMA Authorised: Capecitabine Accord (capecitabine) — Accord Healthcare S.L.U.
The EMA authorised Capecitabine Accord (capecitabine) by Accord Healthcare S.L.U. for breast cancer, colorectal cancer, and stomach cancer, …
-
EMA approval · 2025-05-05EMA Authorised: Ecansya (previously Capecitabine Krka) (capecitabine) — Krka, d.d., Novo mesto
The EMA authorised Ecansya, a capecitabine product by Krka, as a new generic cancer treatment option for breast, colon, colorectal, and gast…
-
EMA approval · 2025-05-02EMA Authorised: Xeloda (capecitabine) — CHEPLAPHARM Arzneimittel GmbH
The EMA authorised CHEPLAPHARM Arzneimittel GmbH to market Xeloda (capecitabine) in the EU for several cancers, including breast, colon/colo…
-
EMA approval · 2025-05-02EMA Authorised: Capecitabine Medac (capecitabine) — medac Gesellschaft für klinische Spezialpräparate mbH
EMA authorised Capecitabine Medac for colorectal cancer. Medac Gesellschaft für klinische Spezialpräparate mbH is the marketing authorizatio…
-
FDA approval · 2025-04-17FDA Approved: AHZANTIVE — Supplemental Application (Valorum Biologics, LLC)
The FDA approved a supplemental application for AHZANTIVE (aflibercept-MRBB) from Valorum Biologics, LLC.